Vivos Therapeutics, Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||
| Net Income | $-21.2M | $-11.1M | $-13.6M | $-23.8M | $-20.3M | $-12.1M | $-10.8M |
| Depreciation & Amortization | $1.3M | $581.0K | $621.0K | $669.0K | $733.0K | $718.0K | $751.2K |
| Depreciation | $700.0K | $500.0K | $600.0K | $600.0K | $400.0K | $300.0K | $326.8K |
| Amortization | $600.0K | $100.0K | $100.0K | $100.0K | $300.0K | $400.0K | $424.4K |
| Stock-Based Compensation | $661.0K | $762.0K | $1.1M | $2.4M | $2.7M | $2.2M | $2.0M |
| Net Cash from Operating Activities | $-15.3M | $-12.7M | $-11.9M | $-19.6M | $-15.7M | $-5.7M | $-5.3M |
| Investing Activities | |||||||
| Capital Expenditures | $2.3M | $568.0K | $803.0K | $924.0K | $2.4M | $120.0K | $175.6K |
| Business Acquisitions | — | — | — | — | $225.0K | — | — |
| Net Cash from Investing Activities | $-7.5M | $-568.0K | $-853.0K | $-924.0K | $-2.6M | $-120.0K | $86.2K |
| Financing Activities | |||||||
| Dividends Paid | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $18.6M | $17.9M | $10.9M | — | $24.2M | $23.5M | $4.5M |
| Net Change in Cash | $-4.2M | $4.6M | $-1.9M | $-20.5M | $5.8M | $17.7M | $-785.4K |
| Free Cash Flow | $-17.6M | $-13.3M | $-12.7M | $-20.5M | $-18.1M | $-5.8M | $-5.5M |